Lung Cancer

Brian Mitzman, MD, FACS, FCCP, discusses the emergence of immunotherapy as a treatment option for patients with early-stage non–small cell lung cancer.

Anne Chiang, MD, PhD, discusses recent advancements in the biological understanding and treatment of small cell lung cancer.

Brian S. Henick, MD, discusses the importance of expanding on the current knowledge of biomarkers and the tumor microenvironment to enhance treatment approaches for patients with non–small cell lung cancer.

Brian Henick, MD, discusses the different ways to identify biomarkers of immunotherapy response in patients with lung cancer and how refining these approaches may improve individualized treatment approaches in the future.

Amy L. Cummings, MD, discusses the significance of the phase 3 FLAURA trial evaluating osimertinib in locally advanced or metastatic non–small cell lung cancer (NSCLC).

Luis Paz-Ares, MD, PhD, highlight adverse events to monitor with pembrolizumab in this setting as well as its role in the treatment landscape.

Timothy Burns, MD, PhD, discusses the evolving use of antibody-drug conjugates in HER2-mutant non–small cell lung cancer.

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

Edward B. Garon, MD, MS, discusses the use of PD-L1 inhibitor and CTLA-4 inhibitor combinations in non–small cell lung cancer.

Patritumab deruxtecan elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer and patients with HER3-expressing metastatic breast cancer.

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

Brian Mitzman, MD, FACS, FCCP, discusses findings from the phase 3 CheckMate 816 trial in patients with resectable non–small cell lung cancer.

RBN-2397, a PARP7 inhibitor, was found to be well tolerated and have preliminary antitumor activity as monotherapy in patients with advanced solid tumors, including head and neck squamous cell carcinoma, breast cancer, and squamous cell carcinoma of the lung.

A coformulation of pembrolizumab and vibostolimab did not elicit a statistically significant improvement in progression-free survival vs docetaxel in pretreated patients with metastatic non–small cell lung cancer.

Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple next-generation sequencing tests per patient.

In this sixth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the consideration of adverse effects related to treatment with TKIs patients in non–small cell lung cancer.

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

First-line treatment with the combination of pembrolizumab and chemotherapy generated a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone in patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.

Osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo as adjuvant treatment for patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer after complete tumor resection with curative intent.

In this fifth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses instances where oral etoposide could be utilized for patients with small cell lung cancer.

The FDA has approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

Khaled Hassan, MD, discusses the importance of performing precise molecular profiling in patients with lung cancer and the need to identify individually tailored treatment approaches.

In this fourth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the management of immune-related adverse effects and the goal of mitigating steroid use for patients with lung cancer.

The FDA has accepted a supplemental biologics license application for neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy, followed by adjuvant pembrolizumab monotherapy, for the treatment of patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer.